EP2380600A1 - Polymer-gleitmaterial, k?nstliches gelenkglied, medizinisches ger?t und herstellungsverfahren daf?r - Google Patents

Polymer-gleitmaterial, k?nstliches gelenkglied, medizinisches ger?t und herstellungsverfahren daf?r Download PDF

Info

Publication number
EP2380600A1
EP2380600A1 EP09835034A EP09835034A EP2380600A1 EP 2380600 A1 EP2380600 A1 EP 2380600A1 EP 09835034 A EP09835034 A EP 09835034A EP 09835034 A EP09835034 A EP 09835034A EP 2380600 A1 EP2380600 A1 EP 2380600A1
Authority
EP
European Patent Office
Prior art keywords
polymer
substrate
medical appliance
polymer substrate
artificial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP09835034A
Other languages
English (en)
French (fr)
Other versions
EP2380600A4 (de
EP2380600B1 (de
Inventor
Masayuki Kyomoto
Kazuhiko Ishihara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyocera Corp
University of Tokyo NUC
Original Assignee
University of Tokyo NUC
Kyocera Medical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Tokyo NUC, Kyocera Medical Corp filed Critical University of Tokyo NUC
Publication of EP2380600A1 publication Critical patent/EP2380600A1/de
Publication of EP2380600A4 publication Critical patent/EP2380600A4/de
Application granted granted Critical
Publication of EP2380600B1 publication Critical patent/EP2380600B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F2/00—Processes of polymerisation
    • C08F2/46—Polymerisation initiated by wave energy or particle radiation
    • C08F2/48—Polymerisation initiated by wave energy or particle radiation by ultraviolet or visible light
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F291/00—Macromolecular compounds obtained by polymerising monomers on to macromolecular compounds according to more than one of the groups C08F251/00 - C08F289/00
    • C08F291/18—Macromolecular compounds obtained by polymerising monomers on to macromolecular compounds according to more than one of the groups C08F251/00 - C08F289/00 on to irradiated or oxidised macromolecules
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/31504—Composite [nonstructural laminate]
    • Y10T428/31855—Of addition polymer from unsaturated monomers

Definitions

  • the present invention relates to a polymer sliding material to be used as a material for medical materials.
  • the present invention particularly relates to a polymer sliding material which is capable of maintaining the properties of wear resistance, load supportability and fracture resistance for a long period of time, which is applicable to an artificial joint that restores human joints, and artificial joints which are made of the sliding material.
  • the present invention relates to medical appliances, particularly to medical tools which contact with blood and biotissues inside and/or outside of the body, such as a blood pump for an (auxiliary) artificial heart, an artificial valve, a stent and a pacemaker as well as dental implants.
  • polyethylene mainly ultrahigh molecular weight polyethylene, hereinafter referred to as PE
  • PE ultrahigh molecular weight polyethylene
  • lysis of bone i.e. osteolysis
  • loosening in which the fixing force of an artificial joint and a bone becomes weaker arose, and the loosening had become a big problem as complication of an arthroplasty.
  • Usual abrasion loss of the above-mentioned PE was about 0.1 to 0.2 mm per year, and there was no problem for a certain period of time (for example, for about several years) after the arthroplasty.
  • the amount of the above-mentioned loosening became remarkable after a lapse of about five years, and thus a re-operation of exchanging the artificial joint should be needed, and that could impose a heavy burden on the patients.
  • the size of a femoral head component has been enlarged for the purpose of improving the range of motion and of prevention of dislocation. Since there is a limit for the size of a cup to be housed in an acetabulum, thinning of (the thickness of) the acetabular cup made of PE has been required corresponding to the enlarging the size of the femoral head component. There was a limit in advancing the thinning of the acetabular cup due to the viewpoints of the properties of wear resistance, deformation resistance and fracture resistance.
  • CLPE crosslinked PE wherein molecular chains are crosslinked thereamong
  • Patent Documents 1 to 3 These researches utilize the matter that irradiating a polymer material with a radiation having high energy such as an electron beam or a gamma ray generates free radicals due to cutoff of molecular chains, followed by occurring the recombination or crosslinking reaction of the molecular chains.
  • the above-mentioned CLPE is excellent in the property of wear resistance compared with the conventional PE, so that it is reported that the amount of the abrasion loss can be reduced even to the order of about one fifth to one tenth of the conventional amount.
  • PEEK polyetheretherketone
  • the property of wear resistance of PEEK itself is not so sufficient, the property is intended to be improved by composting PEEK with a carbon fiber.
  • use of rigid carbon fiber may damage the femoral head component to be combined therewith, and thus a PEEK material having sufficient properties for the artificial joints has not been obtained.
  • an artificial joint component made from a polymeric material which is excellent in reducing the abrasion of the artificial joint and is capable of suppressing the generation of wear debris than ever before can be obtained by grafting a polymerizable monomer having a phosphoryl choline group onto the slidable surface of the artificial joint made from PE (Patent Document 5) .
  • a photopolymerization initiator for example, benzophenone (BP) was used.
  • BP benzophenone
  • a "grafting from” method, wherein the surface of the substrate is used as the starting point of graft polymerization, is advantageous in achieving high densification of the graft layer compared with the other techniques, and it is necessary to preliminarily apply the polymerization initiator to the surface of the substrate which should be treated in order to realize this method.
  • Patent Document 5 discloses an invention to use CLPE as a substrate, 2-methacryloyloxyethyl phosphorylcholine (MPC) as a monomer and BP as a photopolymerization initiator, thereby causing MPC graft polymerization on the surface of the substrate to form a membrane of a layer or MPC on the surface thereof.
  • MPC 2-methacryloyloxyethyl phosphorylcholine
  • the MPC polymer produced by the method of Patent Document 5 is useful as the material for forming an ideal biocompatible surface.
  • the product therefrom is used as a biocompatible material, it is desirable that no photopolymerization initiator remains on the surface of the substrate and in the graft polymer layer after performing the graft polymerization reaction. Therefore, according to the method of Patent Document 5, there was another problem that the radical initiator remaining after performing the graft polymerization reaction should be removed from the surface of the substrate and the graft polymer layer.
  • metal materials used for the medical appliance for example, an artificial kidney, an artificial lung, an artificial trachea, and a blood pump for an (auxiliary) artificial heart, an artificial valve, an artificial blood vessel, a catheter, a cardiac pacemaker, an artificial bone, an artificial tendon, an artificial knuckle and a bone securing plate, a bone screw and so on
  • an artificial kidney, an artificial lung, an artificial trachea, and a blood pump for an (auxiliary) artificial heart, an artificial valve, an artificial blood vessel, a catheter, a cardiac pacemaker, an artificial bone, an artificial tendon, an artificial knuckle and a bone securing plate, a bone screw and so on almost satisfies the condition of the mechanical properties, but they are not always sufficient to the biocompatibility (including the hemocompatibility).
  • biocompatibility including the hemocompatibility
  • an agent which suppresses the protective response of the body is required in therapeutic interventions using the medical appliance in clinical practice.
  • Side effects caused by prolonged use of the above-mentioned agent are serious problems.
  • side effects caused by frequent use of anticoagulant agents include internal bleeding in the skin, nose bleeding, bleeding from the gums, excessive bleeding from the wound, bleeding such as hypermenorrhea, bloody sputum, hematuria, hematochezia as well as dizziness and wobble.
  • bleedings such as gastrointestinal bleeding, intracranial bleeding and intraperitoneal bleeding may place the patient's life in peril when finding of such bleedings would be delayed.
  • a material having the biocompatibility is essential for the developments of the medical appliance which can be embedded in a living body and used therein for a long period of time.
  • a method to use a biologically active substance capable of inhibiting thrombus formation is used so as to impart antithrombotic properties to a surface of a medical device, for example, an artificial organ.
  • a biologically active substance such as urokinase having a function of dissolving thrombus thus formed, heparin capable of inhibiting a function of thrombin as a coagulation factor, or prostaglandin as a platelet activation inhibitor to a surface of a material.
  • a biologically active substance such as urokinase having a function of dissolving thrombus thus formed, heparin capable of inhibiting a function of thrombin as a coagulation factor, or prostaglandin as a platelet activation inhibitor.
  • the side effects caused by these agents can not be disregarded and is a big problem.
  • it is extremely difficult to control the releasing rate of the agent and the effects therefrom cannot be expected after release of the agents.
  • a non-biodegradable polymers including, for example, poly (n-butyl methacrylate), poly (dimethyl siloxane) and so on.
  • polymers which remain on the surface of the stent after the drug eluted may cause an inflammatory reaction and/or a thrombus formation, and also cause a problem of failing to endothelize on the surface of the stent.
  • a method utilizing a biological reaction is employed. That is, it is a method in which coagulation factors and platelets are moderately aggregated to a surface of a material to form a thrombus membrane, and endothelial cells constituting a vascular wall are engrafted on the thrombogenic membrane as a footing and a thin neointima is formed on the surface of the material by further growth of the endothelial cells.
  • a thrombus may occur during the period of about one month after an operation until endothelial cells will cover a medical appliance. Then, it became necessary to administer an antiplatelet drug and thus the side effect caused by the drug cannot be neglected.
  • thrombotic properties are obtained by surface properties of the material per se without using a biologically active substance or a drug.
  • thrombus formation occurs due to an adsorption of a plasma protein and a subsequent activation of platelets, and the adsorption of the plasma protein onto the surface of the material physicochemically proceeds.
  • Such a reforming method includes, for example, a method in which a water-soluble polymer is bonded by a coupling reaction utilizing functional groups such as hydroxyl and amino groups of the surface of the material.
  • Patent Document 7 a method of fixing a random copolymer which consists of an allylamine and a group analogous to a phosphorylcholine group for a medical material is disclosed (Patent Document 7).
  • the content of the phosphorylcholine group on the surface of the medical material decreases, thereby causing a problem that each of the biocompatibility (including the hemocompatibility), the hydrophilicity and the surface lubricity could not be attained to a satisfactory extent.
  • Non-Patent Document 1 it is reported that, in an artificial heart which was coated with an MPC copolymer, merely 5% of MPC copolymer remained after use thereof for ninety-one days (Non-Patent Document 1).
  • Another reforming method includes a method in which peroxide as a polymerization initiator is produced on a surface of a material by irradiating with ultraviolet rays, electric beams or ion beams in the presence of oxygen, and then a water-soluble vinyl monomer is subjected to radical polymerization to form a water-soluble polymer chain on the surface of the material . It is reported that this water-soluble polymer chain prevents a protein from being directly contacted with the surface of the material and inhibits the adsorption of the protein onto the surface of the material.
  • Patent Document 8 it is reported that anti-protein adsorption property can be improved by grafting MPC as a monomer on a polyethylene surface through irradiation with ultraviolet rays.
  • Patent Document 2 it is designed to improve the wear resistant property of a substrate through imparting the surface of the substrate with highly slidability by causing graft polymerization of MPC onto PE using PE without ketone group as the substrate, MPC as a reactive monomer and BP as a photopolymerization initiator.
  • a dental implant there has conventionally been carried out a prosthetic treatment with retrievable partial denture or bridge denture for repairing a loss of teeth due to periodontal diseases and dental caries.
  • retrievable partial denture has an aesthetic problem attributed from a metal hook and a problem of providing a feeling of resistance to implementation
  • bridge denture has a problem that burden for abutment tooth to be ground cannot be avoided.
  • a dental implant treatment has attracted special interest recently as a prosthetic treatment and is one of selection choices, and the number of cases has remarkably increased. In loss of teeth due to fracture of an alveolar bone, teeth are lost together with the alveolar bone around teeth and thus bone width and bone height enough to carry out embedding of implant were not often obtained.
  • a bone grafting method a guided bone regeneration (GBR) method, a bone lengthening method, a bone prosthetic material, and a bone augmentation method utilizing cytokines, thus increasing the number of cases of application of a dental implant.
  • GLR guided bone regeneration
  • a bone lengthening method a bone prosthetic material
  • a bone augmentation method utilizing cytokines
  • CLPE shows an excellent wear resistant property rather than PE, but the period of use thereof is so short that it is not sufficiently confirmed whether it can maintain the wear resistant property for a long period of time.
  • CLPE or surface-modified PE is used for the material of an artificial joint, it may be expected to show an excellent wear resistant property.
  • thinning of the acetabular cup has a limitation according to the viewpoints of the properties of deformation resistance and fracture resistance.
  • the coating layer of the random copolymer when the technique of fixing the coating layer of the random copolymer to the surface of the medical appliance made of PE according to Patent Document 4 would be applied to a sliding member of an artificial joint, it is highly possible that the coating layer of the random copolymer would be peeled from the surface of PE under the rigorous friction and wear environment, so that it is difficult to put it into practical use. It is conceivable that these peeling could be resulted from the low bonding force between the surface of PE and the coating layer of the random copolymer.
  • the coating layer of the random copolymer wherein the polymerization reaction has been sufficiently advanced is designed to immobilize to the surface of PE. However, there is no functional group for bonding with the coating layer of the random copolymer to be polymerized on the surface of the PE, and thus a sufficient bonding force seems not to be obtained.
  • Patent Document 5 succeeded in improving the bonding force between a polymer chain having a phosphoryl choline group and the surface of PE by graft bonding the polymer chains onto the surface of PE.
  • Patent Document 5 The method of Patent Document 5 is shown by the following scheme 1:
  • Patent Document 6 which do not use the polymerization initiator uses a high-energy radiation, and such a high-energy radiation per se has an increased risk. Furthermore, a large-scale and a special equipment is required for management of the radiation source, so that there is a problem in respect of the safety and the economical efficiency.
  • Patent Document 6 As the period of time after irradiation until the substrate, in which radicals generated, contacts with the monomers, the amount of the available radicals decreases. Thus, there is a possibility of failing to obtain a desired and sufficient grafting density (for example, 0.01 chains/nm 2 or more). There also remains a problem that the substrate degrades (or embrittles) along with the irradiation of the radiation such as gamma ray.
  • the grafting density is described in " New Frontiers in Polymer Synthesis" Advances in Polymer Science, VOL. 217, 2008 .
  • Patent Document 8 The method of Patent Document 8 is shown by the scheme 1 illustrated above.
  • the substrate is still made of PE, so that there is a certain limitation in reduction in thickness and in weight of the substrate in order to secure a sufficient strength of the substrate.
  • the present invention has been made in consideration of the above-mentioned problems and has the object of providing a medical appliance excellent in antithrombotic property and slidability, which hardly forms thrombus and the like, thereby for example, being capable of eliminating use of the drugs inhibiting a biological defense reaction, even where the appliance directly contacts with the biotissues inside and/or outside of the body and such a condition is maintained for a long period of time, and the production method therefor. It is desirable that the above medical appliance is excellent for the functions such as cellular adhesion inhibiting potency, biocompatibility, antibacterial properties (inhibition of biofilm formation and adhesion) and so on. Furthermore, it is yet another object of the present invention to provide a dental implant, which demonstrates cellular adhesion inhibiting effect and which is capable of inhibiting the periodontal diseases and the deposition of dental plaque.
  • the inventors on the one hand, focused on the matter that a membrane obtained through polymerizing the monomers containing phosphoryl choline groups shows similar behavior to the cellular membrane, and on the other hand, found the matter that the monomers having vinyl groups such as acrylates can be graft polymerized on the surface of the polymer substrate having ketone groups thereon, and then the above objects have been attained by combining the above matters.
  • the present application provides, as a first invention, an invention of a polymer sliding material comprising a polymer substrate (A) having ketone groups on the surface thereof and a coating layer (B) which coats at least a portion of the surface of the polymer substrate (A), wherein the coating layer (B) is formed by a surface graft polymerization comprising immersing the polymer substrate (A) in a reaction system containing a monomer (C), irradiating the polymer substrate (A) with light, thereby polymerizing the monomer from the surface of the substrate.
  • the present application provides, as a second invention, an invention of an artificial joint component made of the polymer sliding material of the first invention, wherein a polymer substrate (A) constructs the proximal of the artificial joint component, and a coating layer (B) is formed on at least the sliding face of the artificial joint component.
  • the present application provides, as a third invention, an invention of an artificial joint, which is made of the artificial joint component of the above second invention.
  • the present application provides, as a fourth invention, an invention of a medical appliance material comprising a biocompatible material layer (B) covering at least a portion of the surface of the polymer substrate (A) having ketone groups on the surface thereof, wherein the biocompatible material layer (B) is formed by a surface graft polymerization comprising immersing the polymer substrate (A) in a reaction system containing a monomer (C) , irradiating the polymer substrate (A) with light, thereby polymerizing the monomer from the surface of the substrate.
  • the present application provides, as a fifth invention, an invention of a medical appliance produced with using the medical appliance material of the above fourth invention.
  • the present application provides, as a sixth invention, an invention of a method of producing a medical appliance material comprising a polymer substrate (A) and a coating layer (B) which coats at least a portion of the surface of the polymer substrate (A), the method comprising immersing a polymer substrate (A) in a reaction system containing a monomer (C) for forming a biocompatible material layer (B), irradiating the polymer substrate (A) with light, thereby initiating initiating the polymerization of the monomer from the surface of the polymer substrate (A), wherein the polymer substrate (A) is a polymer having ketone groups on the surface thereof, and the reaction system containing the monomer (C) as well as the surface and the inside of the polymer substrate (A) includes no polymerization initiator.
  • the polymer sliding material of the first invention in one embodiment, may be characterized in that the coating layer (B) is formed through the graft polymerization without including a polymerization initiator in the surface and inside of the polymer substrate (A) and the reaction system containing the monomer (C).
  • the polymer sliding material of the first invention in one embodiment, can be characterized in that the polymer substrate (A) is the polymer substrate having an aromatic ketone.
  • the polymer substrate (A) is a polymer selected from the group consisting of polyether ketone (PEK), PEEK, polyether ketone ketone (PEKK), Polyetheretherketone ketone (PEEKK), polyether ketone ether ketone ketone (PEKEKK) and poly aryl ether ketone (PAEK) , a composited polymer wherein at least two kinds of polymers from the above group are composited, and a fiber-reinforced polymer formed by a polymer selected from the above polymer and the composited polymer.
  • the monomer (C) is selected from (meth)acrylate compounds.
  • the monomer (C) is at least a compound selected from the group consisting of an epoxy (meth)acrylate compound, an urethane (meth)acrylate compound, a polyester (meth)acrylate compound, a polybutadiene (meth)acrylate compound and a silicone (meth)acrylate compound.
  • the monomer (C) contains a compound having a phosphoryl choline group.
  • the compound having a phosphoryl choline group is MPC.
  • the surface graft polymerization was performed in a solvent which disperses or dissolves the monomer (C) without dissolving the polymer substrate (A).
  • the polymer sliding material of the first invention shows the coefficient of dynamic friction in a range from 0.01 to 0.04 under the load of 0.98N, the slide distance of 25 mm, the bounce frequency of 1 Hz, the room temperature and the water lubrication environmental condition.
  • the polymer substrate (A) constructs at least a portion of an artificial joint component, for example, the whole or a part of the acetabular cup and/or the whole or a part of the bone head portion of the artificial joint.
  • the coating layer (B) has a thickness of 10 to 200 nm.
  • the surface of the sliding material shows a static water-contact angle of not more than 20° using a sessile drop method under the conditions in which the contact angle was measured after 60 seconds.
  • each concentration of a phosphorus atom and a nitrogen atom on the surface of the sliding material measured by X-ray photoelectron spectroscopy is not less than 4 atom %.
  • An artificial joint component of the second invention in one embodiment thereof, is an artificial joint component produced by polymer sliding material of the first invention, wherein the polymer substrate (A) constructs the base portion of the artificial joint component and at least a sliding face of the artificial joint component is coated with a coating layer (B) .
  • the ball head to be combined has a thickness of not less than 32 mm and the polymer substrate has a thickness in the range from 3 to 6mm.
  • An artificial joint of the third invention in one embodiment thereof, can be characterized by being formed from the artificial joint component.
  • a biocompatible material layer (B) is formed through the graft polymerization without including a polymerization initiator in the surface and inside of the polymer substrate (A) and the reaction system containing the monomer (C).
  • the polymer substrate (A) is the polymer substrate that contains an aromatic ketone.
  • the polymer substrate (A) is a polymer selected from the group consisting of PEK, PEEK, PEKK, PEEKK, PEKEKK and PAEK, a composited polymer wherein at least two kinds of polymers from the above group are composited, and a fiber-reinforced polymer formed by a polymer selected from the above polymer and the composited polymer.
  • the monomer (C) is selected from (meth)acrylate compounds.
  • the monomer (C) is at least one compound selected from the group consisting of an epoxy (meth)acrylate compound, an urethane (meth)acrylate compound, a polyester (meth)acrylate compound, a polybutadiene (meth)acrylate compound and a silicone (meth)acrylate compound.
  • the monomer (C) contains a compound having a phosphoryl choline group.
  • the compound having a phosphoryl choline group is MPC.
  • the surface graft polymerization was performed in a solvent which disperses or dissolves the monomer
  • the surface of the biocompatible material layer (B) shows the coefficient of dynamic friction in a range from 0.01 to 0.04, preferably from 0.01 to 0.02 using a Pin-on-plate type friction tester under the load of 0.98N, the slide distance of 25 mm, the bounce frequency of 1 Hz, the room temperature and the water lubrication environmental condition.
  • the biocompatible material layer (B) has a thickness of 10 nm to 1 micrometer, preferably at least 50 nm, more preferably at least 100 nm up to about 250 nm, more preferably up to about 200 nm.
  • the surface of the biocompatible material layer (B) shows a static water-contact angle of not more than 40°, preferably not more than 20°, more preferably not more than 10°using a sessile drop method under the conditions in which the contact angle was measured after 60 seconds.
  • the surface each concentration of a phosphorus atom and a nitrogen atom on the surface of the biocompatible material layer (B) measured by X-ray photoelectron spectroscopy is not less than 4 atom %, preferably not less than 4.5 atom %, more preferably not less than 5.0 atom %.
  • the adsorption of protein (albumin or fibrinogen) of the surface of the biocompatible material layer (B) obtained through the micro BCA method is not more than 0.2 microgram/ cm 2 , preferably not more than 0.1 microgram/cm 2 , more preferably not more than 0.08 microgram/cm 2 .
  • a medical appliance can be formed by forming a portion, which forms the fundamental skeleton of each medical appliance, is made of a polymer substrate (A), and coating a portion of the surface of the polymer substrate (A), which may directly contact with the biotissues including blood and body fluid, with a biocompatible material layer (B).
  • the medical appliance of the fifth invention in one embodiment thereof, is selected from the group consisting of an artificial kidney, an artificial lung, an artificial trachea, and a blood pump for an (auxiliary) artificial heart, an artificial valve, an artificial blood vessel, a catheter, a cardiac pacemaker, a dental implant, an artificial tooth, an artificial bone, an artificial tendon, an artificial knuckle, a bone securing plate, a bone screw and so on.
  • a biocompatible material layer (B) is formed through the graft polymerization without including a polymerization initiator in the surface and inside of the polymer substrate (A) and the reaction system containing the monomer (C).
  • the polymer substrate that contains an aromatic ketone is used as the polymer substrate (A).
  • the monomer (C) is selected from (meth)acrylate compounds.
  • the monomer (C) is at least one compound selected from the group consisting of an epoxy (meth)acrylate compound, an urethane (meth)acrylate compound, a polyester (meth)acrylate compound, a polybutadiene (meth)acrylate compound and a silicone (meth)acrylate compound.
  • the monomer (C) contains a compound having a phosphoryl choline group.
  • the compound having a phosphoryl choline group is MPC.
  • the surface graft polymerization was performed in a solvent which disperses or dissolves the monomer (C) without dissolving the polymer substrate (A).
  • the polymer substrate and the coating layer formed through polymerizing monomers are bonded (covalently bonded) by graft polymerization, so that a polymer sliding material which can be manufactured safely and economically and is excellent in the durability, which is capable of maintaining the wear resistant property for a long period of time, can be provided.
  • a polymer sliding material excellent in the durability which is capable of preventing remarkable decrease of the wear resistant property for a long period of time such as over five to ten years when applied to an artificial joint can be provided.
  • a polymer substrate having ketone groups on the surface thereof such as PEEK, which is an engineering plastic which is excellent in deformation resistance and fracture resistance, is used as the polymer substrate, a polymer sliding member having less thickness can be provided, while attaining a sufficient wear resistance property, load support property and fracture resistance property even when the thickness of the polymer substrate would be made relatively thinner.
  • the artificial joint component having the properties of the polymer sliding material of the above first invention can be provided.
  • the polymer substrate and the coating layer formed through polymerizing monomers are bonded (covalently bonded) by graft polymerization, so that an artificial joint component which can be manufactured safely and economically and is excellent in the durability, which is capable of maintaining the wear resistant property for a long period of time, can be provided.
  • an artificial joint component excellent in the durability which is capable of preventing remarkable decrease of the wear resistant property for a long period of time such as over five years when applied to an artificial joint can be provided.
  • an artificial joint member having less outer diameter can be provided, while attaining a sufficient load support property and fracture resistance property even when the thickness of the polymer substrate would be made relatively thinner.
  • the artificial joint having the properties of the artificial joint member of the above second invention can be provided.
  • the polymer sliding material of the first invention can demonstrate the durability and slidability (good wettability to water, a low coefficient of dynamic friction and a low coefficient of static friction) by coating the given surface of the polymer substrate that can show desired function and characteristics (for example, durability, load support property and deformation resistance) with a layer of a polymer product having desired function and characteristics (for example, high hydrophilicity, lubricity, protein adsorption inhibition property, cellular adhesion inhibiting effect, water resistance, heat resistance).
  • desired function and characteristics for example, durability, load support property and deformation resistance
  • desired function and characteristics for example, high hydrophilicity, lubricity, protein adsorption inhibition property, cellular adhesion inhibiting effect, water resistance, heat resistance
  • a strong bond between the polymer substrate (A) and the biocompatible material layer (B) can be maintained over a long period of time, since the polymer substrate and the biocompatible material layer, which were formed by polymerizing the monomers, are covalently bonded by the graft polymerization.
  • the biocompatible material layer (B) formed on the polymer substrate (A) demonstrates an excellent biocompatibility by showing the property which is similar to that of a cell membrane, while can show an excellent anti-thrombus property. Therefore, the medical appliance material obtained can maintain the outstanding biocompatibility, anti-thrombus property, cell adhesion inhibition property, biofilm formation inhibition property, and antibacterial property over a long period of time.
  • the medical appliance formed using the medical appliance material can also maintain the same outstanding characteristics such as biocompatibility, anti-thrombus property, cell adhesion inhibition property, biofilm formation inhibition property and antibacterial properties over a long period of time.
  • the above medical appliance materials can eliminate the efforts and the necessity to separate and remove the residual components of the polymerization initiator from the polymerized product, when the graft polymerization is performed in the absence of the polymerization initiator on the surface and inside the polymer substrate (A) and the reaction system during polymerization. Furthermore, when a slight amount of the polymerization initiator remains in the biocompatible material layer and the the biocompatible material layer contacts with biotissues, there is a possibility that the medical appliance (having the biocompatible material layer) may damage the health of the patient, to whom the medical appliance is applied. However, such a possibility that may damage the health of the patient can be substantially prevented or excluded by the medical appliance of the present invention.
  • the medical appliance material uses the polymer substrate having ketone groups on the surface thereof, such as PEEK, which is an engineering plastic which is excellent in deformation resistance and fracture resistance, as the polymer substrate, so that a polymer substrate having less thickness may be formed, while attaining a sufficient wear resistance, load support property and fracture resistance property, even when the thickness of the polymer substrate would be made relatively thinker. Therefore, the medical appliance formed using the medical appliance material can attain further downsizing and/or further thinning and/or further light-weighting.
  • PEEK polymer substrate having ketone groups on the surface thereof, such as PEEK, which is an engineering plastic which is excellent in deformation resistance and fracture resistance, as the polymer substrate, so that a polymer substrate having less thickness may be formed, while attaining a sufficient wear resistance, load support property and fracture resistance property, even when the thickness of the polymer substrate would be made relatively thinker. Therefore, the medical appliance formed using the medical appliance material can attain further downsizing and/or further thinning and/or further light-weighting.
  • the medical appliance material and the medical appliance each of which shows excellent anti-thrombus property, cell adhesion inhibition property, biocompatibility and biofilm formation inhibition property, antibacterial properties as well as safety and durability as mentioned above can be produced comparatively economically.
  • the medical appliance material in the fourth invention can demonstrate the durability and slidability (good wettability to water, a low coefficient of dynamic friction and a low coefficient of static friction) by coating the given surface of the polymer substrate that can show desired function and characteristics (for example, durability, load support property and deformation resistance) with a layer of a polymer product having desired function and characteristics (for example, high hydrophilicity, lubricity, protein adsorption inhibition property, cellular adhesion inhibiting effect, water resistance, heat resistance).
  • desired function and characteristics for example, durability, load support property and deformation resistance
  • desired function and characteristics for example, high hydrophilicity, lubricity, protein adsorption inhibition property, cellular adhesion inhibiting effect, water resistance, heat resistance
  • the medical appliance When the medical appliance is made of using the medical appliance material in the fourth invention or according to the method of sixth invention, the medical appliance excellent in antithrombotic property and slidability, which hardly forms thrombus and the like, thereby for example, being capable of eliminating use of the drugs inhibiting a biological defense reaction, even where the appliance directly contacts with the biotissues inside the body.
  • the dental field it is capable of providing a medical appliance as a dental implant, which demonstrates cellular adhesion inhibiting effect and which is capable of inhibiting the periodontal diseases and the deposition of dental plaque.
  • the graft polymerization method used in the present invention is basically characterized in that the surface of the polymer substrate (A) having a ketone group on the surface thereof is used as a reaction field, wherein a reaction system including the monomer (C) is made to exist on the surface of the polymer substrate (A).
  • the present graft polymerization method is also characterized in that it uses no polymerization initiator, for example, no photo radical type initiator.
  • the solvent may be used or not depending on the combination of the polymer substrate (A) and the monomer (C). However, in order to cause a radical reaction to occur uniformly in the reaction system as a whole, it is preferable to disperse or dissolve the radical monomer (C) in a suitable solvent.
  • the reaction system in such a case includes the solvent in which the monomer (C) is dispersed or dissolved. It is preferable to use a suitable solvent for the above-mentioned graft polymerization reaction system.
  • a polymerization product (branched polymer) is formed on the substrate (trunk) by the graft polymerization, wherein a covalent bond exists between the substrate and the polymerization product.
  • a substrate having an aromatic ketone can be used as the polymer substrate (A) which has a ketone group on the surface thereof.
  • a polymer material selected from the group consisting of PEK, PEEK, PEKK, PEEK, PEKEKK and PEAK can be mentioned.
  • the substrate may be composited with a carbon fiber such as polyacrylonitrile.
  • the ratio of the carbon fiber is preferably in the range from 30 to 60%, and further preferably in an amount of 30%.
  • a vinyl compound for example, (meth) acrylate compound can be used as the monomer (C) .
  • the monomer generally has a radical reactivity, it may have the other reactivity, for example, an ionic reactivity (cationic reactivity or anioninc reactivity).
  • the (meth) acrylate compound can be copolymerized by using independently or in combination with a plurality of compounds. It is capable of producing the polymerization product as the copolymer of a (meth) acrylate compound and a malediction compound by using a mixture with a vinyl compound and a malediction compound depending on the necessity.
  • the above monomer includes, for example, (meth)acrylic acid; an alkyl (meth)acrylic acid such as methyl (meth)acrylate, ethyl (meth)acrylate, n-propyl (meth)acrylate, isopropyl (meth)acrylate, n-butyl (meth)acrylate, isobutyl (meth)acrylic acid, tert-butyl (meth) acrylate, n-pentyl (meth)acrylate, n-hexyl (meth)acrylate, cyclohexyl (meth)acrylate, n-heptyl (meth)acrylate, n-octyl (meth)acrylate, 2-ethylhexyl (meth)acrylate, nonyl (meth)acrylate, decyl (meth)acrylate, dodecyl (meth)acrylate, stearyl (meth)acrylate; phenyl (me
  • the monomer includes a compound having a phosphoryl choline group.
  • the compounds having a phosphoryl choline group includes 2-methacryloyloxyethylphosphorylcholine, 2-acryloyloxyethyl phosphorylcholine, 4-methacryloyloxybutyl phosphorylcholine, 6-methacryloyloxyhexyl phosphorylcholine, omega-methacryloyloxyethylene phosphorylcholine, 4-styryloxybutyl phosphorylcholine and the like.
  • the compounds having a phosphoryl choline group includes MPC. Especially MPC is preferable.
  • the used amount of the reaction system containing the monomer is from 0.01 to 10 ml, preferably, for example, from 0.01 to 5 ml per square cm of surface area of the polymer substrate. It is preferable that the monomer concentration is from 0.25 to 1.00 mol/L, and more preferably from 0.25 to 0.50 mol/L.
  • the polymerization product may have a structure which is similar to that of a cell membrane. Therefore, the material comprising the predetermined polymer substrate, wherein an intended section of the surface of the substrate is coated with such a polymerization product formed by the graft polymerization, is useful as a biomaterial that is used for producing prosthesis or implanting in a living body.
  • biotissues for example, an artificial kidney, an artificial lung, a pump for artificial heart, a catheter and a cardiac pacemaker, in that the excellent biocompatibility thereof may be utilized then they are used as the material to form the parts that directly contacts with the biotissues including blood and body fluid.
  • the solvents suitable for the present graft polymerization method include water, alcohols and aqueous solution of those alcohols.
  • the solvent to be used is required to satisfy the conditions that at least the monomers are dissolved or dispersed therein; the substrate is neither eroded nor dissolved thereby; and the present graft polymerization will not be adversely affected thereby.
  • the light that can be used in the present graft polymerization method is an ultraviolet or a visible ray (hereinafter, also merely referred to as "UV ray"), which preferably has a wavelength in a range from 200 to 450 nm and more preferably has a wavelength in the range from 200 to 450 nm.
  • the intensity of UV ray is preferably in a range from 1.5 to 8.0 mW/cm 2 , for example, in a range from 4.0 to 6.0 mW/cm 2 .
  • the irradiation time is preferably in a range from 20 to 180 minutes and more preferably in a range from 45 to 90 minutes.
  • the present photo-graft polymerization can be suitably performed according to the above conditions.
  • radicals are generated by irradiating the intended surface of the polymer substrate with light energy during the graft polymerization reaction. Compared with the case using a radiation, it is easy to control the range of irradiation in the case using light. Therefore, it is possible to select the area where the graft polymerization is performed is limited to an intended section on the surface of the polymer substrate by using a mask and the like.
  • the polymerization product formed in the shape of a film on the surface of a polymer substrate can have the thickness in the range of 10 nm to 1 micrometer, for example, a thickness of 50 nm to 200 nm, depending of the necessity.
  • the polymerization product formed on the surface of the polymer substrate through the present graft polymerization method generally has a thickness from 10 nm to 1 micrometer.
  • the ratio of the amount of the monomer to be used to the polymer substrate can be obtained by calculating the amount of the number of moles or the weight of the monomers that corresponds to the thickness of the coating of the polymerization product intended to be formed to the surface area of the polymer substrate to which the polymerization product intended to be attached. For example, it is capable of using an amount of from about 0.0001 to about 1.0 mol of the monomers per square cm of surface area of the polymer substrate .
  • the graft density (chains/nm 2 ) can be adjusted according to the conditions that are used in the polymerization.
  • the graft density is preferably in the range from 0.01 to 0.6 chains/nm 2 , particularly in the range from 0.05 to 0.6 chains/nm 2 .
  • Example 1 PEEK was used as the substrate, MPC was used as the monomer and water was used as the solvent for suspending the monomers.
  • the PEEK specimen (length 10 cm X width 1 cm X thickness 0.3 cm; weight 3. 9 g: trade name 450G (manufactured by VICTREX) used as the substrate was ultrasonically cleaned in ethanol, thereby the surface was cleaned. Separately, 0.5 mol/L aqueous solution of MPC was prepared. The above-prepared aqueous MPC solution was introduced into a quartz glass vessel in an amount of 15 mL.
  • the PEEK specimen was immersed therein.
  • the PEEK specimen was irradiated with UV ray having a wavelength of 300 to 400 nm for 90 minutes, thereby performed the graft polymerization reaction. After irradiating with ultraviolet rays, the PEEK specimen was picked up from the aqueous MPC solution, sufficiently rinsed with pure water and dried.
  • Example 2 the same procedure as Example 1 was performed except that a carbon fiber compound PEEK (CF-PEEK) sample (length 10 cm X width 1 cm X thickness 0.3 cm; weight 4.2 g: trade name CK4600 (manufactured by Sumitomo Chemical Co., Ltd.) as the substrate.
  • CFRPEEK carbon fiber compound PEEK
  • Comparative Example 1 In order to compare with Example 1, Comparative Example 1 was performed. In Comparative Example 1, the same procedure as Example 1 was performed except that a polyethylene (PE) sample (length 10 cm X width 1 cm X thickness 0.3 cm; weight 2.6 g: trade name GUR1020 (manufactured by POLY HI SOLIDUR) as the substrate.
  • PE polyethylene
  • Example 3 BP was added to the reaction system of Example 1 as the polymerization initiator.
  • BP was dissolved in an acetone solution so that the concentration thereof becomes 10 g/L.
  • the PEEK specimen using as the substrate was picked up therefrom and dried, thereby a PEEK substrate on which surface BP was coated was obtained.
  • the graft polymerization reaction was performed in the same manner as the method of Example 1. The difference from Example 1 was the procedure that BP was applied onto the surface of substrate before the graft polymerization reaction.
  • Example 4 BP was added to the reaction system of Example 2 as the polymerization initiator.
  • BP was dissolved in an acetone solution so that the concentration thereof becomes 10 g/L.
  • the CF-PEEK specimen using as the substrate was picked up therefrom and dried, thereby a CF-PEEK substrate on which surface BP was coated was obtained.
  • the graft polymerization reaction was performed in the same manner as the method of Example 1.
  • BP was used for the reaction system of the comparative example 1 as a polymerization initiator. It dissolved in the acetone solution so that it might become 10 g/L about BP at the beginning. After PE sample used for obtained BP / acetone solution as substrate was immersed for 30 seconds, PE substrate with which BP was applied to the surface was obtained by pulling up and drying an acetone solution. The graft polymerization reaction was made to perform like the method of Example 1 using this.
  • Example 1 Each of the products from Example 1 and Example 3 was subjected to Fourier-transform infrared (FT-IR) analysis with total reflection method (ZnSe prism) by using FT-IR analyzer Type 615 (manufactured by JASCO Co. Ltd.) at a revolution of 4 cm -1 for 32 times of integration. The results are shown in Fig. 1 .
  • FT-IR Fourier-transform infrared
  • Fig. la shows, from the top thereof sequentially, the results of PEEK used as the substrate (thus untreated), MPC graft polymerized PEEK product (PEEK-g-MPC, where BP was used) obtained from Example 3, and MPC graft polymerized PEEK product (PEEK-g-MPC, where BP was not used) obtained from Example 1 without using BP, respectively. From Fig. la, it has been confirmed that each PEEK substrate in each product obtained from Example 1 and Example 3 has not been deteriorated through each operation. Fig.
  • lb indicates the difference of the spectrum chart of the PEEK used as the substrate (thus untreated) from the spectrum chart of the MPC graft polymerized PEEK product (PEEK-g-MPC, where BP was not used) obtained from Example 1 without using BP by overlapping them.
  • the peaks (1060 or 1720 cm -1 ) derived from MPC were found on the surface of the PEEK product obtained from Example 1 where the graft polymerization was performed without using the photopolymerization initiator (BP). Therefore, it could be confirmed that MPC could be graft polymerized on the surface of the PEEK in the case where the photopolymerization initiator was not used.
  • Example 1 The product from Example 1 was subjected to XPS analysis using an XPS spectrophotometer (AXIS-HSi165; manufactured by KRATOS ANALYTICAL) equipped with a 15-kV Mg K-alpha radiation source under the conditions using applied voltage of 15 kV and photoelectron emission angle of 90 degrees.
  • XPS spectrophotometer AXIS-HSi165; manufactured by KRATOS ANALYTICAL
  • Fig. 2 the results of the surface elemental composition is shown in Table 1.
  • the peak (-N + (CH 3 ) 3 ) derived from MPC was found in any of the PEEK surface that was subjected to the graft polymerization using the photopolymerization initiator (BP) and the PEEK surface that was subjected to the graft polymerization without using the photopolymerization initiator. Therefore, it could be confirmed that MPC also could be graft polymerized on the surface of the PEEK in the case where the photopolymerization initiator was not used. From Fig.
  • the peak (P-O) derived from MPC was found in any of the PEEK surface that was subjected to the graft polymerization using the photopolymerization initiator (BP) and the PEEK surface that was subjected to the graft polymerization without using the photopolymerization initiator. Therefore, it could be confirmed that MPC also could be graft polymerized on the surface of the PEEK in the case where the photopolymerization initiator was not used. In each of N 1s spectrum and P 2p spectrum, the peak derived from MPC was found in the graft polymerized PEEK surface irrespective of the presence or absence of the photopolymerization initiator.
  • the atomic concentration on the surface of the product obtained through the graft polymerization of MPC onto CF-PEEK is found to be substantially equivalent to that of the product obtained from Example 4 wherein photopolymerization initiator was used.
  • Example 3 On the surface of the product of Example 1 and Example 3, the thickness of the MPC polymer membrane obtained through the graft polymerization was measured.
  • the specimen to be used for the measurement was embedded in an epoxy resin, subjected to ruthenium tetrachloride dyeing, and then ultrathin sections were sliced therefrom using an ultramicrotome.
  • TEM transmission electron microscope
  • Model JEM-1010 manufactured by JEOL
  • observation was conducted at an acceleration voltage of 200 kv.
  • the results are shown in Fig. 3 .
  • untreated PEEK is (a)
  • Example 3 is (b)
  • Example 1 is (c).
  • a coating layer (MPC polymer film) or biocompatible material layer was observed on the surface of Example 1 and Example 3, which was not observed in the untreated PEEK.
  • Each thickness of the layer (MPC polymer film) of the product from Examples 1 and 3 was about 100 nm.
  • Each static water-contact angle of the products of Examples 1-4 and Comparative Examples 1-2 was measured with an optical bench-type contact angle goniometer (model DM300; Kyowa Interface Science Co., Ltd., Japan) using a sessile drop method according to ISO Standard 15989 under the conditions in which drops of purified water (1 ⁇ L) were deposited on each surface of the products and the contact angle was measured after 60 seconds.
  • the static water-contact angle was similarly measured in the untreated state with regard to each polymer substrate. The results are shown in Fig. 4 .
  • the contact angle value of the product from Comparative Example 1 which was obtained by performing the graft polymerization of the MPC to PE substrate without using the photopolymerization initiator was larger than that of the product from Comparative Example 2, which was obtained by performing the graft polymerization of the MPC to PE substrate with using the photopolymerization initiator, and was rather similar to the contact angle value of the untreated PE substrate. From this, it has been shown that the substrate which has no ketone group on the surface thereof is, particularly, not suitable for the method of the present invention wherein a monomer is graft polymerized to a substrate without using a photopolymerization initiator.
  • Fig. 6 is a schematic illustration of an artificial hip joint 1, which is one of the artificial joints produced using the artificial joint component of the present invention.
  • the artificial hip joint 1 comprises a sliding member (an acetabular cup) fixed within an acetabular 94 in a coxal bone 93, and a femoral stem 20 fixed to the proximal end of a femur 91.
  • the acetabular cup 10 comprises a cup substrate 12 which has an acetabular fixing face 14 having almost hemispherical shape and a sliding face 16 having almost hemispherical hollow shape, and a coated layer 30 which coats the sliding face 16.
  • the artificial joint 1 functions as an artificial hip joint by inserting a ball head 22 of the femoral stem 20 into the sliding face 16 of the acetabular cup 10, thereby the both components being able to slidably move with each other.
  • a coating layer 30 was graft polymerized onto the surface to become the sliding face 16 of the cup substrate 12.
  • the thickness of the coating layer 30 was preferably made to be 50 to 200 nm
  • the thickness of the cup substrate 12 was preferably made to be 3 to 6 mm
  • the diameter of the ball head 22 was preferably made to be 40 to 48 mm.
  • Fig. 7 shows a schematic illustration of the range of motion of the artificial joint component of the present invention.
  • Fig. 7(a) shows an example where a diameter of 26 mm was adopted as the ball head which is the maximum size for corresponding to the thickness 13 mm of the cup substrate.
  • Fig. 7(b) shows an example where a diameter of 32 mm was adopted as the ball head which is the maximum size for corresponding to the thickness 10 mm of the cup substrate.
  • Fig. 7(c) shows an example where a diameter of 40 mm was adopted as the ball head which is the maximum size for corresponding to the thickness 6 mm of the cup substrate.
  • the diameter of the ball head was 40 mm and the thickness of the cup substrate was 6 mm, and the range of motion was 143°.
  • the matter that the range of motion of an artificial joint increases means that the artificial joint has a structure which hardly dislocates.
  • the thickness of the cup substrate was conventionally required to be 10 mm or more according to the limitation from the strength thereof, since PE was used as the substrate thereof.
  • a cup having a thickness of 3 to 6 mm may be designed and a sufficient safety relating to the strength can also be secured.
  • the monomers having phosphoryl choline groups and vinyl groups such as acrylates may be graft polymerized onto the surface of the polymer substrate having ketone groups thereon by irradiating with light, and the surface of the artificial joint component produced thereby has a low water-contact angle and a low coefficient of dynamic friction.
  • the artificial joint produced using those artificial joint components could have a structure having a wide range of motion. Therefore, an artificial joint simultaneously having a high lubricity, a biocompatibility and an anti-dislocation function can be provided by applying the polymer sliding component of the present invention.
  • Each protein (albumin) adsorption test of the products of Examples 1 and 3 and Comparative Examples 1 and 2 was measured according to a colorimetric determination method (micro BCA method) using coordination of reduced Cu(+) from Biuret reaction and bicinchoninic acid (BCA) with using high-sensitivity BCA protein assay reagent (BCA-200 Protein Assay Kit) (produced by Thermo Fisher Scientific Inc.) at a condition of 37°C for 1 hour of adsorption time.
  • BCA-200 Protein Assay Kit produced by Thermo Fisher Scientific Inc.
  • Each protein (fibrinogen) adsorption test of the products of Examples 1 and 3 was measured according to the micro BCA method with using high-sensitivity BCA protein assay reagent (BCA-200 Protein Assay Kit) (produced by Thermo Fisher Scientific Inc.) at a condition of 37°C for 1 hour of adsorption time. As a basis for comparison, the same test was performed in each of the polymer substrate in each untreated state. The results are shown in Fig. 9 .
  • the monomers having phosphoryl choline groups and vinyl groups such as acrylates may be graft polymerized onto the surface of the polymer substrate having ketone groups thereon by irradiating with light, and the surface of the medical appliance material produced thereby has significantly low adsorption of protein (albumin or fibrinogen). Therefore, it was confirmed that the medical appliance and the medical appliance material of the present invention can demonstrate excellent properties in an anti-thrombus property, a cellular adhesion inhibiting potency, a biocompatibility, antibacterial properties (inhibition of biofilm formation and adhesion) and so on.
  • the polymer sliding material of the present invention is suitable to apply to an artificial joint component.
  • the artificial joint component of the present invention is suitable to apply to an artificial joint.
  • the acetabular cup which was produced using the artificial joint component of the present invention makes the ball head having a size, which was not conventionally considered to be adequate, available to be used, since it makes the thickness of the acetabular cup per se thin. Therefore, an artificial joint having enlarged range of motion and beign useful for prevention of dislocation may be provided, which is valuable for the medical industry.
  • the medical appliance material (biocompatible polymeric material) of the present invention is suitably applicable to a medical appliance, and in detail, an appliance which contacts with blood and the biotissues inside and/or outside of the body, for example, an artificial kidney, an artificial lung, an artificial trachea, a blood pump for an (auxiliary) artificial heart, an artificial valve, an artificial blood vessel, a catheter, a cardiac pacemaker, an artificial bone, an artificial tendon, an artificial knuckle and a bone securing plate, a bone screw and so on, and a dentistry implant.
  • a medical appliance for example, an artificial kidney, an artificial lung, an artificial trachea, a blood pump for an (auxiliary) artificial heart, an artificial valve, an artificial blood vessel, a catheter, a cardiac pacemaker, an artificial bone, an artificial tendon, an artificial knuckle and a bone securing plate, a bone screw and so on, and a dentistry implant.
  • a medical appliance as a dental implant, which demonstrates cellular adhesion inhibiting effect and which is capable of inhibiting the periodontal diseases and the deposition of dental plaque, and thus being valuable for the medical industry.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dermatology (AREA)
  • Materials For Medical Uses (AREA)
  • Prostheses (AREA)
  • Dental Preparations (AREA)
EP09835034.1A 2008-12-25 2009-12-25 Polymer-gleitmaterial, künstliches gelenkglied, medizinisches gerät und herstellungsverfahren dafür Active EP2380600B1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008330513 2008-12-25
JP2008330504 2008-12-25
PCT/JP2009/071614 WO2010074238A1 (ja) 2008-12-25 2009-12-25 ポリマー摺動材料、人工関節部材、医療器具及びその製造方法

Publications (3)

Publication Number Publication Date
EP2380600A1 true EP2380600A1 (de) 2011-10-26
EP2380600A4 EP2380600A4 (de) 2013-08-21
EP2380600B1 EP2380600B1 (de) 2018-04-18

Family

ID=42287842

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09835034.1A Active EP2380600B1 (de) 2008-12-25 2009-12-25 Polymer-gleitmaterial, künstliches gelenkglied, medizinisches gerät und herstellungsverfahren dafür

Country Status (4)

Country Link
US (1) US8765265B2 (de)
EP (1) EP2380600B1 (de)
JP (1) JP5775694B2 (de)
WO (1) WO2010074238A1 (de)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2468311A4 (de) * 2009-08-20 2014-06-25 Japan Medical Materials Corp In hohem masse schmierfähiges gleitelement und künstliches gelenk damit
EP3626275A4 (de) * 2017-05-17 2021-02-24 Kyushu University, National University Corporation Medizinisches polymermaterial mit hervorragender knochenbindungseigenschaft
EP3919093A4 (de) * 2019-02-27 2022-03-30 TERUMO Kabushiki Kaisha Verfahren zur herstellung eines medizinischen instruments sowie medizinisches instrument

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013005984A (ja) * 2011-06-27 2013-01-10 Kyocera Medical Corp 骨プレート
JP6133017B2 (ja) * 2012-04-27 2017-05-24 京セラメディカル株式会社 膜製造装置及び人工関節コンポーネントの製造方法
JP6061670B2 (ja) * 2012-12-27 2017-01-18 京セラメディカル株式会社 人工関節用摺動部材の製造方法および人工関節用摺動部材
JP6192362B2 (ja) * 2012-05-31 2017-09-06 京セラ株式会社 摺動部材およびその製造方法
JP5936566B2 (ja) * 2013-02-28 2016-06-22 京セラメディカル株式会社 摺動部材の製造方法
EP2856978B8 (de) * 2012-05-31 2017-12-13 KYOCERA Corporation Liner für implantate und verfahren zu seiner herstellung
JP5816222B2 (ja) * 2013-04-25 2015-11-18 住友ゴム工業株式会社 表面改質方法及び表面改質弾性体
GB201506244D0 (en) * 2015-04-13 2015-05-27 Pilkington Group Ltd Coated glazing
JP6602163B2 (ja) * 2015-11-02 2019-11-06 株式会社トクヤマデンタル 接着性ポリアリールエーテルケトン樹脂材料の製造方法、及び接着方法
KR101869961B1 (ko) * 2016-07-28 2018-06-21 한국생산기술연구원 친수성 표면을 갖는 peek 구조체 및 상기 peek 구조체 표면처리방법
KR20180081427A (ko) * 2017-01-06 2018-07-16 고려대학교 산학협력단 인공 관절
US10875250B2 (en) 2017-01-15 2020-12-29 Hexcel Corporation Method for analytically determining laser power for laser sintering
US10926432B2 (en) 2017-01-15 2021-02-23 Hexcel Corporation Polymer powder and method of using the same
WO2019107372A1 (ja) * 2017-11-28 2019-06-06 国立大学法人東京大学 芳香族ポリエーテルケトン基材の表面改質方法
JP7285532B2 (ja) * 2017-11-28 2023-06-02 国立大学法人 東京大学 芳香族ポリエーテルケトン基材の表面改質方法
JP7223366B2 (ja) * 2019-01-30 2023-02-16 三菱重工業株式会社 表面改質方法、接着方法、表面改質材料及び接合体

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2204197A1 (de) * 2007-10-03 2010-07-07 Japan Medical Materials Corporation Bioverträgliches verschleissarmes material, künstliches gelenk damit und herstellungsverfahren dafür

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2984203B2 (ja) 1995-10-31 1999-11-29 京セラ株式会社 人工関節用摺動部材の製造方法
RU2211008C2 (ru) 1996-02-13 2003-08-27 Массачусетс Институт Оф Текнолоджи Протезные устройства из полиэтилена сверхвысокой молекулярной массы, обработанного облучением и плавлением
US6228900B1 (en) 1996-07-09 2001-05-08 The Orthopaedic Hospital And University Of Southern California Crosslinking of polyethylene for low wear using radiation and thermal treatments
EP1211268B1 (de) 1999-07-14 2006-11-29 Nof Corporation Statistisches copolymer, verfahren zu dessen herstellung und medizinisches material
JP4156945B2 (ja) 2002-02-19 2008-09-24 株式会社神戸製鋼所 高分子材料製人工関節部材
ATE486619T1 (de) 2002-02-19 2010-11-15 Kobe Steel Ltd Künstliches gelenkglied aus einem polymeren material
JP4111794B2 (ja) * 2002-09-30 2008-07-02 富士フイルム株式会社 親水性部材
JP5130052B2 (ja) * 2005-11-29 2013-01-30 京セラメディカル株式会社 血液ポンプ
EP1987849B1 (de) * 2006-02-06 2016-11-23 Kyocera Medical Corporation Gleitelement mit geringem abrieb und dieses verwendendes künstliches gelenk
JP4963838B2 (ja) 2006-02-06 2012-06-27 京セラメディカル株式会社 低摩耗性摺動部材及びそれを用いた人工関節
JP5100023B2 (ja) * 2006-03-29 2012-12-19 京セラメディカル株式会社 生体材料、及びそれを用いた人工関節並びにその製造方法
JP5545609B2 (ja) * 2006-08-24 2014-07-09 独立行政法人日本原子力研究開発機構 芳香族高分子膜基材からなる高分子電解質膜、及び、その製造方法
JP4849999B2 (ja) * 2006-08-30 2012-01-11 株式会社ビー・アイ・テック 人工股関節用複合材製ソケット
US20080097606A1 (en) * 2006-10-19 2008-04-24 Cragg Andrew H Knee joint prosthesis and hyaluronate compositions for treatment of osteoarthritis
US20080119762A1 (en) 2006-11-16 2008-05-22 Tateishi Tadasu Guide wire
JP2008125523A (ja) * 2006-11-16 2008-06-05 Terumo Corp 医療用器具
JP2009235060A (ja) 2008-03-04 2009-10-15 Sumitomo Chemical Co Ltd 気液分散装置及び気液分散方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2204197A1 (de) * 2007-10-03 2010-07-07 Japan Medical Materials Corporation Bioverträgliches verschleissarmes material, künstliches gelenk damit und herstellungsverfahren dafür

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MASAYUKI KYOMOTO ET AL: "Self-initiated surface graft polymerization of 2-methacryloyloxyethyl phosphorylcholine on poly(ether ether ketone) by photoirradiation", ACS APPLIED MATERIALS,, vol. 1, no. 3, 1 January 2009 (2009-01-01) , pages 537-542, XP008154069, DOI: 10.1021/AM800260 *
MASAYUKI KYOMOTO ET AL: "Self-initiated surface grafting with poly(2-methacryloyloxyethyl phosphorylcholine) on poly(ether-ether-ketone)", BIOMATERIALS, ELSEVIER SCIENCE PUBLISHERS BV., BARKING, GB, vol. 31, no. 6, 1 January 2010 (2010-01-01), pages 1017-1024, XP008154073, ISSN: 0142-9612, DOI: 10.1016/J.BIOMATERIALS.2009.10.055 [retrieved on 2009-11-10] *
See also references of WO2010074238A1 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2468311A4 (de) * 2009-08-20 2014-06-25 Japan Medical Materials Corp In hohem masse schmierfähiges gleitelement und künstliches gelenk damit
EP3626275A4 (de) * 2017-05-17 2021-02-24 Kyushu University, National University Corporation Medizinisches polymermaterial mit hervorragender knochenbindungseigenschaft
US11542367B2 (en) 2017-05-17 2023-01-03 Kyushu University, National University Corporation Medical polymer material having excellent bone-bonding property
EP3919093A4 (de) * 2019-02-27 2022-03-30 TERUMO Kabushiki Kaisha Verfahren zur herstellung eines medizinischen instruments sowie medizinisches instrument

Also Published As

Publication number Publication date
US20120022665A1 (en) 2012-01-26
EP2380600A4 (de) 2013-08-21
JP5775694B2 (ja) 2015-09-09
JPWO2010074238A1 (ja) 2012-06-21
WO2010074238A1 (ja) 2010-07-01
EP2380600B1 (de) 2018-04-18
US8765265B2 (en) 2014-07-01

Similar Documents

Publication Publication Date Title
US8765265B2 (en) Polymer sliding material, artificial joint member, medical appliance, and manufacturing method therefor
US9034414B2 (en) Biomaterial, joint prosthesis using the biomaterial and method of producing the same
EP1893703B1 (de) Hydrophile polymerbeschichtungen für medizintechnische vorrichtungen
EP1858438B1 (de) Nachgiebige polymere beschichtungen für einführbare medizinische artikel
US6387379B1 (en) Biofunctional surface modified ocular implants, surgical instruments, medical devices, prostheses, contact lenses and the like
EP2233159B1 (de) Medizinische vorrichtung und verfahren zu ihrer herstellung
US9192694B2 (en) Biocompatible and low-abrasion member, and artificial joint using the same and method of producing the same
JP6702939B2 (ja) 架橋されたポリホスホリルコリンでコーティングされた体内挿入用補形物および同体内挿入用補形物をコーティングする方法
KR101880576B1 (ko) 생체적합성 임플란트
US20080057298A1 (en) Low friction particulate coatings
US20200155723A1 (en) Highly hydrophilic coatings for biomedical applications
DK2986330T3 (en) IMPLANTS TO INDUCT SOFT AND HARD TISSUE INTEGRATION
Du et al. The effect of POSS-COOH/silicone rubber (SR) on the adipogenesis differentiation of mesenchymal stem cells
WO2006107336A1 (en) Bioactive coating compositions for medical devices
Ortiz et al. Preparation of a novel anti shrinking agent (SOC DA) and its evaluation in dental resins

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110719

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20130718

RIC1 Information provided on ipc code assigned before grant

Ipc: A61L 27/00 20060101AFI20130712BHEP

17Q First examination report despatched

Effective date: 20160115

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE UNIVERSITY OF TOKYO

Owner name: KYOCERA CORPORATION

RIN1 Information on inventor provided before grant (corrected)

Inventor name: KYOMOTO, MASAYUKI

Inventor name: ISHIHARA, KAZUHIKO

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20171109

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 989754

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180515

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602009051907

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20180418

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180718

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180718

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180719

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 989754

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180418

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180820

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602009051907

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

26N No opposition filed

Effective date: 20190121

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20181225

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181225

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20181231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181231

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181225

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181225

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181231

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181225

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180418

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20091225

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180418

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180818

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230505

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20231206

Year of fee payment: 15